SG/CALL/GILEAD SCIENCES/90/0.1/20.06.25 Stock

SG/CALL/GILEAD SCIENCES/90/0.1/20.06.25 Share Price

DE000SU2YPP5

Market Closed - Boerse Frankfurt Warrants 20:45:58 17/05/2024 BST
0.14 ^EUR	-6.67%

Current month	+15.38%
1 month	-21.05%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart SG/CALL/GILEAD SCIENCES/90/0.1/20.06.25

Latest news about GILEAD SCIENCES, INC.

Transcript : Gilead Sciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 10:30 AM	05-15
Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	05-14
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy	05-14	BU
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	05-09	BU

More news

Quotes 5-day view

Date	Price	Change
17/05/24	0.15	0.00%
16/05/24	0.15	0.00%
15/05/24	0.15	-6.25%
14/05/24	0.16	0.00%
13/05/24	0.16	+14.29%

Real-time Boerse Frankfurt Warrants

Last update May 17, 2024 at 08:45 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Société Générale
WKN	SU2YPP
ISIN	DE000SU2YPP5
Date issued	29/11/2023
Strike	90 $
Maturity	20/06/2025 (399 Days)
Parity	10 : 1
Emission price	0.41 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.97 €
Lowest since issue	0.11 €
Spread	0.01 €
Spread %	6.25%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company